GDF15 and Cachexia: Preliminary phase 1b data suggest that suppression of GDF‐15 with ponsegromab may lead to improvement in cachexia‐related symptom burden, building on promising preclinical observations in animal tumour models where neutralization of GDF‐15 reverses anorexia and weight loss and improves muscle function and survival.8, 18, 19, 22